Anlon Healthcare Share Price: Profit Zero Par! Revenue **50%** Gira, CFO Bhi Gaya?

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorIshaan Verma|Published at:
Anlon Healthcare Share Price: Profit Zero Par! Revenue **50%** Gira, CFO Bhi Gaya?
Overview

Arre bhai, Anlon Healthcare ke Q3 FY25 results ne toh sabko hila diya! Company ka net profit seedha **₹0 Lakhs** par aa gaya, jo pichhle saal isi quarter mein **₹19.75 Lakhs** tha. Revenue bhi gir ke **₹3,557.80 Lakhs** ho gaya, matlab **50.1%** ka bada dip.

Q3 FY25 mein company ka revenue ₹3,557.80 Lakhs raha, jo pichhle saal ke ₹7,135.95 Lakhs se 50.1% kam hai. Profit toh ₹0 Lakhs pe pahunch gaya, jabki pichhle saal isi quarter mein ₹19.75 Lakhs tha. Lagta hai margins par bahut pressure aaya hai iss quarter mein.

Agar 9 mahine (9M FY25) ka hisab lagayein toh revenue mein thodi badhotri dikhi hai, 0.66% badhkar ₹12,107.65 Lakhs ho gaya hai (pichhle saal 9M FY24 mein ₹12,028.66 Lakhs tha). Lekin profit mein 38.5% ki substantial giriwat aayi hai, ab woh ₹2,200.87 Lakhs hai jo pichhle 9 mahine mein ₹3,614.74 Lakhs tha.

Ab sabse badi khabar yeh hai ki company ke CFO, Mr. Hitesh Bavanjibhai Makwana, ne 09 February 2026 se resign kar diya hai. Reason 'pre-occupation' bataya gaya hai. Aur ek Independent Director, Mr. Shailesh Kantilal Thakkar, bhi health issues aur busy hone ke karan board se chale gaye hain.

Par company ne turant action liya hai. Mr. Naimish Dilipbhai Bhatt, jinhe finance mein 18 saal se zyada ka experience hai, unhe naya CFO banaya gaya hai. Aur Mr. Kishan Vinodkumar Raja, jo ek Chartered Accountant hain aur jinke paas 14 saal ka experience hai, woh naye Independent Director bane hain.

Achhi baat yeh hai ki IPO ke paison ka hisab-kitaab bilkul clear hai. Statutory auditors RVD & Co. ne confirm kiya hai ki IPO se mile ₹12,103.00 Lakhs ka fund sahi jagah istemal hua hai jaisa prospectus mein bataya tha, koi deviation nahi mili. Aur haan, December 31, 2025 tak ₹2,523.96 Lakhs IPO funds abhi bhi bache hain.

Abhi investors ki nazar Anlon Healthcare par hogi ki woh Q3 ke is bure performance ko kaise sudharte hain. Naye CFO aur board kya strategies late hain, aur company profits kaise improve karti hai, yeh dekhna important hoga.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.